Company Overview and News
As chief executive of the world’s biggest asset manager, Larry Fink began the year with a call to the thousands of companies that the firm holds stakes in: Show how they make a “positive contribution to society.” Now Fink’s BlackRock Inc., overseeing more than $6 trillion of other people’s money, is facing a comparable challenge, stuck between conscience and the implacable demands of the bottom line.
BGX DGLD BGLF CS HSB UGLD SCGLF MS HSBC HBCYF DSLV VIIX CSSLF VIIZ SCGLY BX HCS BGB 0005 CSGKF BLK HSEA CLNY HSEB ZIV USLV GLE TVIX XIV
HSBC Holdings has begun revisiting a plan to list its shares on the mainland, putting it on track to become first foreign company to issue depositary receipts on the mainland under the scheme that links the Shanghai and London stock exchanges.
HSB 0005 HSEA HSEB HCS HSBC HBCYF
Oct 19 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
RDS.B RDS.A BNPQY RDSB SFTBF BNPQF RDSA HCS HSB 0005 BNPZY RYDBF HSEA HSEB 9984 RYDAF HSBC SFTBY DIS HBCYF
HSBC Holdings PLC is set to be the first company to issue Chinese Depository Receipts (CDRs), through a link between the London and Shanghai stock exchanges which will begin by year-end, people familiar with the matter told Reuters on Thursday.
STAN UL UNLYF ULVR UN HCS UNLNF HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC HBCYF
Benchmark gauge closes at lowest since November 2014 as fears grow that shares pledged as collateral will face forced sales, fuelling further losses
SCHYF WYNMF HSNGF HCS 0011 1128 HSB 0005 HSNGY HSEA 1928 HSEB SCHYY HSBC WYNMY HBCYF
ABU DHABI/LONDON: Anglo-Gulf Trade Bank, a British/UAE start-up, is aiming to shake up trade finance in the region by using blockchain to speed up transactions, becoming the latest financial services firm to adopt the technology.
STAN HCS HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC HBCYF
Chicago, IL –October 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Altria (MO - Free Report) , U.S. Bancorp (USB - Free Report) ,Biogen (BIIB - Free Report) , Ecolab (ECL - Free Report) and HSBC Holdings (HSBC - Free Report) .
STZ.B STZ HCS USB HSB 0005 BIIB HSEA HSEB URBN HSBC ECL HBCYF
NEW YORK, Oct 11 — A US prosecutor yesterday urged jurors in Manhattan federal court to find three former London-based currency traders guilty of scheming to rig prices, kicking off the latest trial to emerge from a US probe into the multitrillion-dollar foreign exchange market.
BCS BNPQY HSB 83SF 83SK UBS HSBC HBCYF 47MC C BNPQF HCS 0005 BNPZY CGBBW HSEA HSEB ULSGF
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LRCX HD LMT GD SCCO UTX HCS USB HSB 0005 BIIB HSEA HSEB HSBC ECL HBCYF
UBS Group AG goes on trial in Paris on Monday accused of encouraging rich clients to stash cash overseas to evade French taxes by deploying tactics “worthy of James Bond.”
HSB 0005 UBS HSEA HSEB HCS HSBC ULSGF HBCYF
Capital One (COF - Free Report) remains well positioned to grow, driven by consistent top-line rise, improving earnings performance and strong balance sheet position. Further, it has an impressive capital deployment plan. Yet, deteriorating asset quality and higher expense levels are major concerns for Capital One. Despite these headwinds, this Zacks Rank #2 (Buy) stock seems like an attractive investment opportunity right now as it has been witnessing solid upward estimate revisions.
GEC GE HCS YY HSB 0005 HSEA HSEB GNE HSBC HBCYF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HSBC / HSBC Holdings Plc on message board site Silicon Investor.
|HSBC (NYSE:HBC) a new era begins||HSBC (NYSE:HBC) a new era begins||HSBC (NYSE:HBC) a new era begins|
as of ET